findmyKOL

John Heymach, MD, PhD

Enriched profile

Chair, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine; Professor of Thoracic/Head and Neck Medical Oncology & Cancer Biology (joint appointment) · The University of Texas MD Anderson Cancer Center

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Houston, TX · South Central · United StatesSpecialtyMedical OncologyFocusLung Cancer Treatments and Mutations+4
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2011–2026

John Heymach is Chair, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine; Professor of Thoracic/Head and Neck Medical Oncology & Cancer Biology (joint appointment) at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 2,459 publications with 69,203 citations (h-index 131); ClinicalTrials.gov lists 6 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Medical Oncology profiles in the findmyKOL directory. Clarivate lists John Heymach as a Highly Cited Researcher (Clinical Medicine, 2022-2024).

Data verified 14 Aug 2026

Overview

Updated 16 Oct 2026

John Heymach, M.D., is Chair, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, Houston, TX. The public record shows 2,459 publications with 69,203 citations (h-index 131), centered on Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 37 companies, 10 NIH-funded awards (2011–2026).

  • Most recent indexed publication: 2026 · Nature communications
  • Top research focus: Lung Cancer Treatments and Mutations
  • 6 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 37 companies

Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Lung Cancer (NSCLC/SCLC)6 trialsSmall Cell Lung Carcinoma2 trialsAdenocarcinoma of Lung1 trialCarcinoma, Small Cell1 trial

Research focus

OpenAlex concept fingerprint
Lung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersLung Cancer Research StudiesCancer Genomics and DiagnosticsRNA modifications and cancer

Drugs & molecules

across trials, industry payments and publications
Imfinzigeneric · DurvalumabClinical trials2Industry payments24Publications2Opdivogeneric · NivolumabClinical trials2Industry payments3Publications5Tagrissogeneric · OsimertinibClinical trials—Industry payments15Publications3Krazatigeneric · AdagrasibClinical trials—Industry payments5Publications1IpilimumabClinical trials1Industry payments—Publications4Tepmetkogeneric · TepotinibClinical trials—Industry payments3Publications2Enhertugeneric · TrastuzumabClinical trials1Industry payments3Publications—CisplatinClinical trials2Industry payments—Publications1CarboplatinClinical trials1Industry payments—Publications1Lynparzageneric · OlaparibClinical trials1Industry payments1Publications—PaclitaxelClinical trials1Industry payments—Publications1Libtayogeneric · CemiplimabClinical trials—Industry payments53Publications—

Works with

trial sponsors and companies reporting payments
Regeneron Pharmaceuticals, Inc.Clinical trials—Industry payments52AstraZeneca Pharmaceuticals LPClinical trials—Industry payments50Boehringer Ingelheim International GmbHClinical trials—Industry payments37Janssen Biotech, Inc.Clinical trials—Industry payments34BioNTech SEClinical trials—Industry payments19GlaxoSmithKline, LLC.Clinical trials—Industry payments19AstraZeneca UK LimitedClinical trials—Industry payments14Boehringer Ingelheim Pharmaceuticals, Inc.Clinical trials—Industry payments12E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments12Merck KGaAClinical trials—Industry payments10Takeda Pharmaceuticals U.S.A., Inc.Clinical trials—Industry payments10Jazz Pharmaceuticals Inc.Clinical trials—Industry payments9RefleXion Medical, Inc.Clinical trials—Industry payments8Abbvie Inc.Clinical trials—Industry payments7Janssen Global Services, LLCClinical trials—Industry payments7EMD Serono, Inc.Clinical trials—Industry payments6Genentech USA, Inc.Clinical trials—Industry payments6Mirati Therapeutics, Inc.Clinical trials—Industry payments6Pfizer Inc.Clinical trials—Industry payments6Blueprint Medicines CorporationClinical trials—Industry payments5Chugai Pharmaceutical Co., Ltd.Clinical trials—Industry payments5Eli Lilly and CompanyClinical trials—Industry payments5Genentech, Inc.Clinical trials—Industry payments5AstraZenecaClinical trials3Industry payments—M.D. Anderson Cancer CenterClinical trials3Industry payments—Daiichi Sankyo Inc.Clinical trials—Industry payments2Genzyme CorporationClinical trials—Industry payments2Hexal AGClinical trials—Industry payments2OPKO Pharmaceuticals, LLCClinical trials—Industry payments2Sanofi Us Services Inc.Clinical trials—Industry payments2

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
2,459publications

Distinct works indexed by OpenAlex, matched via ORCID; 98 in PubMed.

69,203citations

Total citations across indexed works.

131h-index

Hirsch index (OpenAlex). i10-index 555.

Clinical & industry

trials, payments and federal funding
6clinical trials

Investigator role on registered studies.

View trials ↓
37companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
10NIH grants · 2011–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 16 Oct 2026

Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:

All 6 trial records: search, sort and filter.Explore →

Industry payments

Updated 16 Oct 2026

37 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 92 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    83.9%
    Kinase inhibitor83.9%
    Tagrisso100%
    Part D<11 patients

  • Nervous system

    16.1%
    Opioid Agonist16.1%
    Oxycodone Hcl100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 16 Oct 2026

10 NIH research awards on record, funded 2011–2026 per NIH RePORTER. The latest:

All 59 award records: search, sort and filter.Explore →

Publications

Updated 16 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 98 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Lung Cancer
    2,392 citations2008
    doi.org ↗
  2. 02
    <i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma
    1,609 citations2018
    doi.org ↗
  3. 03
    Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
    1,280 citations2019
    doi.org ↗
  4. 04
    Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
    1,271 citations2019
    doi.org ↗
  5. 05
    An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
    1,122 citations2012
    doi.org ↗
All 2,459 cited works: search, sort and filter.Explore →

Network

Updated 16 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Don L. Gibbons818Ignacio I. Wistuba671Jianjun Zhang596Lauren A. Byers557Jing Wang429Lixia Diao398Ferdinandos Skoulidis349Marcelo V. Negrão331Monique B. Nilsson309John D. Minna308Stephen G. Swisher295Ara A. Vaporciyan293Mark M. Awad283Tina Cascone270Hai T. Tran268Xiuning Le264Carmen Behrens259George R. Blumenschein252Biagio Ricciuti250Waree Rinsurongkawong246Natalie I. Vokes244Luc Girard239David S. Hong235J. Jack Lee230Lingzhi Hong226Joao V. Alessi222Giuseppe Lamberti221Boris Sepesi219Junya Fujimoto200Uma Giri184Vadeerat Rinsurongkawong173Jack A. Roth173Edwin R. Parra169Funda Meric‐Bernstam164Bonnie S. Glisson164Qi Wang158Roy S. Herbst157Haniel A. Araújo156Teng Zhou154Minh Truong153

Online presence

Updated 16 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Google Scholar

    scholar.google.com/citations

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholar.google.com ↗
  • ResearchGate

    researchgate.net/profile/John-Heymach

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗

Mentions by others

where others cite or feature them
  • LinkedIn

    linkedin.com/posts/onclive_john-heymach-md-phd-of-md-anderson-cancer-activity-7333628143028576258-r5ok

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
  • Other

    videopodcast.researchtopractice.com/lung-cancer-john-v-heymach-md-phd

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →videopodcast.researchtopractice.com ↗
  • Other

    lung-cancer-update.captivate.fm/episode/5684-oncologytodayheralterednsclc25

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lung-cancer-update.captivate.fm ↗
  • Other

    biotechtv.com/post/john-heymach-september-26-2024

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →biotechtv.com ↗
  • Instagram

    instagram.com/thehappylungsproject/reel/DEPzvi9JbHn

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗
  • X / Twitter

    twitter.com/MDAndersonNews/status/1043144414531596288

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →twitter.com ↗
  • X / Twitter

    x.com/MDAndersonNews/status/1826319192091422758

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 16 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Board Certified

    Medical Oncology, American Board of Internal Medicine

    2005
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Medical Oncology Fellowship

    Dana-Farber/Partners CancerCare Program (Dana-Farber/Mass General Brigham), Boston

    2003
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Internal Medicine Internship & Residency

    Brigham and Women's Hospital, Boston

    2000
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • M.D.

    Stanford University School of Medicine

    1998
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Ph.D.

    Neuroscience, Stanford University School of Medicine

    1996
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • B.A.

    Chemistry (magna cum laude), Harvard University

    1989
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗

Editorial & leadership roles

journal and society appointments
  • Leader

    Lung Cancer Moon Shot program, MD Anderson

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Co-Director/Project Leader

    Lung Cancer SPORE (Specialized Program of Research Excellence)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Chair

    National Cancer Institute Molecular Cancer Therapeutics-1 (MCT-1) study section

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →public.era.nih.gov ↗
  • Member

    American Association for Cancer Research (AACR)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗

Highly Cited Researcher

Clarivate's annual list, by award category and year
  • Clinical Medicine
    202220232024
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • Faculty Member

    UT MD Anderson UTHealth Houston Graduate School of Biomedical Sciences

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →gsbs.uth.edu ↗
  • Member

    Scientific Advisory Board, ModeX Therapeutics

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →modextherapeutics.com ↗
  • Member

    Scientific Advisory Board, Lung Cancer Research Foundation

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lungcancerresearchfoundation.org ↗

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.